The attorneys at Florin Roebig are investigating injuries caused to consumers that have taken the blood thinner Xarelto (rivaroxaban) and who have suffered from side effects including strokes, intracranial hemorrhages, gastrointestinal bleeding, epidural hematoma, adrenal bleeding and other significant bleeding events. There are allegations that Xarelto is more dangerous than traditional blood thinners due to the fact that nothing exists to reverse its blood-thinning effects.
What is Xarelto and what is the problem?
Xarelto is manufactured by Bayer and marketed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, as an anticoagulant, more commonly known as a blood-thinning drug, used to treat patients experiencing clots, deep vein thrombosis (DVT), and pulmonary embolisms (PE). It has been reported that more than eight million prescriptions have been written for Xarelto in the United States. It has been approved for six indications:
- To reduce the risk of strokes and clots in patients with atrial fibrillation not caused by a heart valve problem.
- To treat patients with deep vein thrombosis (DVT).
- To treat patients with pulmonary embolism (PE).
- To reduce the risk of recurrence of DVT or PE following an initial six-month treatment for acute venous thromboembolism.
- To reduce the risk of blood clots in the legs and lungs of patients who just had knee replacement surgery.
- To reduce the risk of blood clots in the legs and lungs of patients who just had hip replacement surgery.
In July 2011, Xarelto (rivaroxaban) was approved by the FDA as a once daily blood-thinning medication. In the FDA’s News Release, it was noted at that time that the most common side effect observed in patients treated with Xarelto was bleeding. Xarelto was originally approved by the FDA as a medication used to prevent blood clots in patients following orthopedic surgery (knee or hip replacements) due to the patients usually having limited mobility for lengths of time following their surgery. When patients remain in a bed or chair for long periods of time they are more likely to develop deep vein thrombosis (DVT), blood clots in the veins in their lower legs. In the event that a clot breaks loose, it can travel in the blood stream and potentially cause injuries such as a heart attack, stroke or pulmonary embolism (PE).
In November 2011, the FDA approved Xarelto to prevent strokes in patients who have abnormal heart rhythm (non-valvular atrial fibrillation). Xarelto was compared against Warfarin, which has been widely used since the mid 1900’s. During the trial, it was found that Xarelto was similar to Warfarin in its ability to prevent a stroke. One main difference between Xarelto and Warfarin is that Warfarin’s effects can be reversed with a dose of Vitamin K. Xeralto has no effective reversal agent. Many lawsuits accuse the manufacturer of downplaying the bleeding and clotting risks of Xarelto.
Do I have a Xarelto Lawsuit?
Florin Roebig is currently accepting Xarelto injury cases from patients throughout the United States. If you or somebody you love has been injured as a result of taking Xarelto, please do not hesitate to contact the experienced attorneys at Florin Roebig. Call us for a consultation at (727) 786-5000 or submit information about your case for an evaluation on our Contact page.
If you are taking Xarelto, you should immediately discuss the health risks with your doctor. Do not stop taking any medication until you have discussed the health risks and benefits of doing so with your physician or health care provider.
At Florin Roebig we are committed to helping those injured by Xarelto and intend to seek the justice they deserve, especially those who have experienced a stroke, cerebral hemorrhage, gastrointestinal bleeding, uncontrollable bleeding, internal bleeding, and death as a result of taking Xarelto. We are currently investigating all such claims.
If you or a loved one has been injured by Xarelto, please do not hesitate to call our office for a free legal consultation at (727) 786-5000 or fill out our case evaluation form on the Contact page of our website.